The prevention and management of herpes zoster

Anthony L Cunningham, Judith Breuer, Dominic E Dwyer, David W Gronow, Robert D Helme, John C Litt, Myron J Levin and C Raina MacIntyre
Med J Aust 2008; 188 (3): 171-176.


  • Anthony L Cunningham1
  • Judith Breuer2
  • Dominic E Dwyer1
  • David W Gronow3
  • Robert D Helme4
  • John C Litt5
  • Myron J Levin6
  • C Raina MacIntyre7

  • 1 Westmead Millennium Institute for Medical Research and University of Sydney, Sydney, NSW.
  • 2 Centre for Infectious Diseases, Barts and The London School of Medicine and Dentistry, London, UK.
  • 3 Pain Services Westmead Hospital and Sydney Pain Management Centre, Sydney, NSW.
  • 4 Western Health, Melbourne, VIC.
  • 5 Department of General Practice, Flinders University, Adelaide, SA.
  • 6 University of Colorado, Boulder, Colo, USA.
  • 7 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead, Sydney, NSW.


The article was developed with an unrestricted educational grant from CSL Limited. The company did not participate in any author meetings nor exert any editorial influence. We thank Dr Robert W Johnson and Professor Margaret Burgess for their review of the draft manuscript, and Wellmark and Dr Candice O’Sullivan for their help in preparing the manuscript.

Competing interests:

The authors were paid an honorarium for their attendance and participation at the roundtable meeting, and their review of the draft manuscript. Travel support was also provided if required. All members of the roundtable group except Myron Levin and Judith Breuer are members of the Zostavax Advisory Board, convened on a regular basis by CSL Limited. Robert Helme is a member of the Neuropathic Pain Lyrica Advisory Board (Pfizer). Raina MacIntyre is a member of the VZV Working Party of the Australian Technical Advisory Group on Immunisation. Myron Levin has received honoraria, consulting fees and research support from Merck, and shares the patent on the herpes zoster vaccine. He has also received research support from GlaxoSmithKline (GSK). John Litt has received travel support and conference registration fees from CSL to attend Infectious Diseases Society of America and varicella-zoster virus meetings in Toronto and Australia. David Gronow has received honoraria for lectures from Mundipharma, Pfizer and Janssen-Cilag, and is a member of advisory boards for Mundipharma, CSL and Medtronic. Judith Breuer has received funding from GSK, Merck Sharpe & Dohme, Sanofi Pasteur, the Wellcome Trust and the United Kingdom Medical Research Council for work on varicella-zoster vaccines. Dominic Dwyer and Anthony Cunningham participate in clinical trials of antiviral agents and vaccines and sit on advisory boards for pharmaceutical companies that produce drugs and vaccines mentioned in this article.

  • 1. Gnann J Jr, Whitley R. Herpes zoster. N Engl J Med 2002; 347: 340-346.
  • 2. International Herpes Management Forum. Johnson RW, Whitely R, editors. Combating varicella zoster virus-related diseases. Herpes 2006; 13 Suppl 1: 1-41.
  • 3. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
  • 4. Gidding HF, MacIntyre CR, Burgess MA, et al. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 2003; 131: 1085-1089.
  • 5. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalisation and pharmaceutical prescribing data to compare the revaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003; 131: 675-682.
  • 6. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 1-12.
  • 7. Ragozzino MW, Melton LF, Kurland LT. Population based study of herpes zoster and its sequelae. Medicine 1982; 61: 310-316.
  • 8. Brisson M, Edmunds W, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305-314.
  • 9. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1-S26.
  • 10. Heininger U, Seward JF. Varicella. Lancet 2006; 368: 1365-1376.
  • 11. Dwyer DE, Cunningham AL. Herpes simplex and varicella-zoster virus infections. Med J Aust 2002; 177: 267-273.
  • 12. Portenay RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol 1986; 20: 651-664.
  • 13. Rawlinson WD, Dwyer DE, Gibbons VL, Cunningham AL. Rapid diagnosis of varicella-zoster virus infection with a monoclonal antibody based direct immunofluorescence technique. J Virol Methods 1989; 23: 13-18.
  • 14. Wood M, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-347.
  • 15. Beutner K, Friedman D, Forszpaniak C, et al. Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546-1553.
  • 16. Tyring S, Barbarash R, Nahlik J, et al. Famciclovir for the treatment of acute herpes zoster: effects on the acute disease and post herpetic neuralgia: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 89-96.
  • 17. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48–72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998; 178 Suppl 1: S81-S84.
  • 18. Whitely R, Weiss H, Gnann J Jr, et al. Aciclovir with and without prednisone for the treatment of herpes zoster. A randomised, placebo-controlled trial. The National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group. Ann Intern Med 1996; 125: 376-383.
  • 19. Wood M, Johnson R, McKendrick M, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900.
  • 20. Board of the Australian Herpes Management Forum. Managing herpes zoster: guidelines for clinicians. 2006. (accessed Mar 2007).
  • 21. International Association for the Study of Pain (IASP) Task Force on Taxonomy. Pain terms: a current list of definitions and notes on usage. In: Merskey H, Bogduk N, editors. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press, 1994: 209-214.
  • 22. Neurology Expert Group. Postherpetic neuralgia. In: Therapeutic guidelines: neurology. Version 3. Melbourne: Therapeutic Guidelines Limited, 2007: 163-165.
  • 23. National Heath and Medical Research Council. The Australian immunisation handbook. Part 2: Vaccination for special risk groups. 8th ed. Canberra: NHMRC, 2003: 69. (accessed Aug 2007).
  • 24. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55: 1499-1507.
  • 25. Lolekha S, Tanthiphabha W, Sornchai P, et al. Effect of climatic factors and population density on VZV epidemiology within a tropical country. Am J Trop Med Hyg 2001; 64: 131-136.
  • 26. Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25: 2139-2144.
  • 27. US Advisory Committee on Immunization Practices. Provisional Recommendations. Use of shingles (herpes zoster) vaccine. Atlanta, Ga: ACIP, 2006. (accessed Aug 2007).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.